The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
Expands bioprocessing footprint across Asia
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Subscribe To Our Newsletter & Stay Updated
